References
- SerupJLindbladAKMarotiMKjellgrenKINiklassonERingLAhlnerJTo follow or not to follow dermatological treatment–a review of the literatureActa Derm Venereol200686319319716710573
- BewleyABurrageDMErsserSJHansenMWardCIdentifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative studyJ Eur Acad Dermatol Venereol201428676377023663069
- AugustinMHollandBDartschDLangenbruchARadtkeMAAdherence in the treatment of psoriasis: a systematic reviewDermatology2011222436337421757881
- CarrollCLFeldmanSRCamachoFTBalkrishnanRBetter medication adherence results in greater improvement in severity of psoriasisBr J Dermatol2004151489589715491434
- FeldmanSRHornEJBalkrishnanRPsoriasis: improving adherence to topical therapyJ Am Acad Dermatol20085961009101618835062
- VangeliEBakhshiSBakerAA systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseasesAdv Ther20153211983102826547912
- TurnerAPWilliamsRMSloanAPHaselkornJKInjection anxiety remains a long-term barrier to medication adherence in multiple sclerosisRehabil Psychol200954111612119618711
- BolgeSCGorenATandonNReasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspectivePatient Prefer Adherence2015912113125653505
- KivitzACohenSDowdJEClinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trialClin Ther200628101619162917157117
- PaulCLacourJPTedremetsLEfficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)J Eur Acad Dermatol Venereol20152961082109025243910
- BayasAImproving adherence to injectable disease-modifying drugs in multiple sclerosisExpert Opin Drug Deliv201310328528723339371
- LugaresiAAddressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?Expert Opin Drug Deliv200969995100219637982
- PozzilliCSchweikertBEcariUOentrichWBetaPlus Study groupSupportive strategies to improve adherence to IFN beta-1b in multiple sclerosis–results of the betaPlus observational cohort studyJ Neurol Sci20113071–212012621636099
- GriffithsCEReichKLebwohlMComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsLancet2015386999354155126072109
- GordonKBlauveltKLangleyRIxekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1)American Academy of Dermatology – 73rd Annual Meeting2015
- Callis DuffinKBagelJBukhaloMPhase 3, open-label, randomized study of the pharmacokinetics, efficacy, and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)J Eur Acad Dermatol Venereol Epub201688
- Humira Patient Instructions for Use Available from: http://www.rxab-bvie.com/pdf/humirapen_PIL.pdfAccessed January 26, 2016
- Enbrel Patient Instructions for Use Available from: http://pi.amgen.com/united_states/enbrel/derm/enbrel_piu.pdfAccessed January 26, 2016
- PachonJAKivitzAJHeuerKUPichlmeierUAssessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritisSAGE Open Med20142205031211456424126770759
- SchiffMKooJJinEUsability and acceptability of the abatacept pre-filled autoinjector for the subcutaneous treatment of rheumatoid arthritisAdv Ther201633219921326833303
- SchwarzenbachFDao TrongMGrangeLLaurentPEAbryHCottenJGrangerCResults of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritisPatient Prefer Adherence2014819920924627625
- ZiemssenTSylvesterLRamettaMRossAPPatient satisfaction with the new interferon Beta-1b autoinjector (BETACONNECT™)Neurol Ther20154212513626662362
- PartschCJSchnabelDEhtishamSJohnstoneHCZabranskyMKiessWAcceptability of the reusable SurePal™ self-injection device for Omnitrope(®) among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational studyMed Devices (Auckl)2015838939326405430